Milestone Pharmaceuticals announced that China's NMPA approved its etripamil nasal spray for PSVT, triggering a $2.0 million milestone payment. This approval opens a significant new market for the drug and strengthens Milestone's partnership with Everest Medicines in Greater China.
Milestone Pharmaceuticals (MIST) announced a significant regulatory win with the NMPA approval of its etripamil nasal spray in China for Paroxysmal Supraventricular Tachycardia (PSVT). This approval is a major positive catalyst for MIST, triggering a $2.0 million milestone payment and opening up a new, large market estimated at 3-6 million patients. Everest Medicines (1952.HK), MIST's partner in Greater China, will lead commercialization and stands to benefit significantly from sales, with MIST also eligible for up to $98.0 million in additional milestones and tiered royalties up to 18%. This long-term opportunity for revenue growth and market penetration is a strong positive for both companies, especially MIST, as it validates their drug outside the US and diversifies their revenue streams.